Key Points A real-world analysis of 470 adults with irritable bowel syndrome with constipation, or IBS-C, found fewer gastrointestinal-related healthcare visits after patients started IBSRELA….
October 12, 2026
NervGen Doses First Participant in Phase 3 RESTORE Study of NVG-291 for Chronic Spinal Cord Injury
NervGen Pharma Corp. (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing treatments for spinal cord injury (SCI), announced on October 12, 2026 that the first…
Key Points Sagimet is presenting long-term results for its experimental acne pill, denifanstat, at a dermatology conference in Las Vegas. A study in China reported…
October 08, 2026
Perspective Therapeutics Wins FDA Fast Track Status for Targeted Therapy in Rare Tumors
Key Points The FDA granted Fast Track designation to PSV359 for adults with FAP-positive solitary fibrous tumors that are locally advanced and unresectable and/or metastatic….
Key Points Armata announced two issued U.S. patents covering treatment methods involving its investigational bacteriophage candidates, AP-SA02 and AP-PA02. The AP-SA02 patent was issued October…
October 06, 2026
Kamada Doubles Israeli Biosimilar Lineup, Targets Up to $25 Million in Annual Revenue by 2030
Key Points Kamada launched Ustekinumab-Kamada and Enoxaparin-Kamada in Israel, expanding its marketed biosimilar portfolio from two products to four. Ustekinumab-Kamada references Stelara, while Enoxaparin-Kamada references…
Key Points Telix administered the first U.S. commercial doses of Pixclara at medical centers in Indianapolis and Cleveland. Pixclara is the only FDA-approved radiopharmaceutical imaging…
Key Points Amylyx will present Phase 3 LUCIDITY topline results for avexitide at ObesityWeek 2026 on November 15. The company previously announced positive topline results…
Key Points OKYO Pharma enrolled the first patients in NEPTUNE, its pivotal Phase 3 trial of urcosimod for neuropathic corneal pain. Melissa Toyos enrolled the…
Key Points Psyence BioMed’s Texas subsidiary, TIRC, signed a manufacturing agreement with Benuvia Operations for planned U.S. production of pharmaceutical-grade ibogaine API. Benuvia operates an…
October 05, 2026
vTv Fully Enrolls Phase 3 Cadisegliatin Trial in Type 1 Diabetes
Key Points vTv Therapeutics has completed enrollment in its Phase 3 CATT1 study of cadisegliatin as an add-on treatment to insulin for adults with type…
October 02, 2026
Surrozen Clears FDA IND Hurdle for DME Drug, Unlocking $95.1 Million Financing Milestone
Key Points The FDA has cleared Surrozen’s investigational new drug application for SZN-8141, enabling clinical development in diabetic macular edema. Surrozen expects to dose the…